Type 2 diabetes is associated with obesity and insulin resistance 1 . The pathophysiology of the insulin-resistant state remains enigmatic, and currently available insulin sensitizers are only partially effective at improving glucose disposal in skeletal muscle and suppressing hepatic gluconeogenesis 2 . A more detailed knowledge of pathways that influence insulin resistance is necessary to identify new targets for the development of anti-diabetic drugs 3 .
Forkhead box-containing transcription factors of the FoxO subfamily are key effectors of insulin action in metabolic processes, including hepatic glucose production (HGP) 4 . Hepatic FoxO1 promotes transcription of genes encoding glucose-6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase (Pck1), the rate-limiting enzymes in hepatic glycogenolysis and gluconeogenesis, respectively 5 . FoxO1 is phosphorylated by Akt, leading to its nuclear exclusion and degradation 6 . In insulin resistance, FoxO1 is constitutively active, leading to increased HGP and fasting hyperglycemia 7 . Despite the importance of FoxO1 in regulation of hepatic insulin sensitivity 8 , it remains a poor candidate for a drug target owing to its lack of a ligand-binding domain and broad transcriptional signature.
Notch receptors mediate cell-fate decisions via interactions among neighboring cells; complexity arises from the presence of four transmembrane receptors (Notch1-Notch4), and five transmembrane ligands of the Jagged/Delta-like families 9 . Upon ligand-dependent activation, a series of cleavage events leads to release and nuclear entry of the Notch intracellular domain (NICD), binding and activation of transcription factor Rbp-Jκ and downstream expression of Notch target genes of the 'Hairy enhancer of split' (Hes) and Hes-related (Hey) families 10 . Mutations in the Notch pathway are etiologic in multiple developmental and neoplastic conditions 11 , such as Alagille syndrome, a human disorder characterized by cholestasis and vascular anomalies 12, 13 . In mice, nullizygosity of Notch1, Jag1 and Rbpj is embryonic lethal, underscoring the developmental requirement for Notch signaling 9, 14, 15 .
We have previously demonstrated that FoxO1 and Rbp-Jκ directly interact, leading to corepressor clearance from and coactivator recruitment to promoters of Notch target genes, which in turn allows differentiation of several cell types 16 . This provides a mechanism for the interaction between the PI 3-kinase-Akt-FoxO1 and Notch-Rbp-Jκ pathways to integrate growth with differentiation. We hypothesized that a similar interaction between these pathways exists in differentiated tissue and modulates FoxO1 metabolic functions. We used loss-of-function mutations in the two pathways, as well as adenovirusmediated gain of function and pharmacological inhibition, to demonstrate that Notch can regulate HGP in a FoxO1-dependent manner.
RESULTS

Foxo1 and Notch1 haploinsufficiency increase insulin sensitivity
To evaluate the physiologic relevance of Notch signaling in liver, we determined relative expression of the four Notch receptors. In wildtype (WT) mouse hepatocytes, predominantly Notch1 and Notch2 were expressed (data not shown). Notch1 activation, as reflected by cleavage at Val1744 and expression of canonical Notch targets, increased with fasting ( Fig. 1a,b ), in parallel with gluconeogenic Transcription factor FoxO1 promotes hepatic glucose production. Genetic inhibition of FoxO1 function prevents diabetes in experimental animal models, providing impetus to identify pharmacological approaches to modulate this function. Altered Notch signaling is evident in tumorigenesis, and Notch antagonists are in clinical testing for application in cancer. Here we report that FoxO1 and Notch coordinately regulate hepatic glucose metabolism. Combined haploinsufficiency of FoxO1 and Notch1 markedly raises insulin sensitivity in diet-induced insulin resistance, as does liver-specific knockout of the Notch transcriptional effector Rbp-Jk. Conversely, Notch1 gain-of-function promotes insulin resistance in a FoxO1-dependent manner and induces glucose-6phosphatase expression. Pharmacological blockade of Notch signaling with g-secretase inhibitors raises insulin sensitivity after in vivo administration in lean mice and in obese, insulin-resistant mice. The data identify a heretofore unknown metabolic function of Notch and suggest that Notch inhibition is beneficial in diabetes treatment, in part by helping to offset excessive FoxO1-driven hepatic glucose production. Fig. 1a,b) , and returned to baseline levels with refeeding. Both Notch1 and Notch2 were induced in db/db mouse liver and with high-fat diet (HFD), resulting in increased Notch target expression ( Supplementary Fig. 1c,d and data not shown). Notch1 activation during fasting and in insulin resistance parallels that of FoxO1. To investigate the functional relationship between these pathways, we generated mice with combined haploinsufficiency of the two genes (Foxo1 +/− ; Notch1 +/− ), which had reduced Notch1 and FoxO1 expression in all tissues (data not shown).
genes (Supplementary
Despite unchanged body mass index, body composition, food intake and oxygen consumption ( Supplementary Fig. 2a-d) , Foxo1 +/− ; Notch1 +/− mice on various diets had lower fasted and fed glucose and insulin levels, suggesting greater insulin sensitivity than WT or Foxo1 +/− mice ( Fig. 1c,d) . Glucose tolerance and insulin sensitivity were greater in chow-fed (data not shown) and HFD-fed Foxo1 +/− ; Notch1 +/− mice ( Fig. 1e,f) . Pyruvate tolerance tests showed decreased conversion of pyruvate to glucose in Foxo1 +/− ; Notch1 +/− mice, suggesting decreased gluconeogenesis ( Fig. 1g) ; this was confirmed by decreased glucose production in primary hepatocytes isolated from Foxo1 +/− ; Notch1 +/− as compared to WT mice ( Fig. 1h) . Hepatic Akt1 and Irs1 phosphorylation was greater in Foxo1 +/− ; Notch1 +/− mice, consistent with greater hepatic insulin sensitivity ( Fig. 1i ). For most parameters tested, Foxo1 +/− mice showed trends similar to those of Foxo1 +/− ; Notch1 +/− mice, but the differences between Foxo1 +/− and WT mice did not reach statistical significance; Notch1 +/− mice did not differ significantly from WT mice in any parameter tested (data not shown).
We detected no difference in β-cell mass or glucose-stimulated insulin release between Foxo1 +/− ; Notch1 +/− and control mice (data not shown), suggesting that metabolic changes are unrelated to β-cell function. We also detected no change in serum glucagon, corticosterone or triglycerides (data not shown), but adiponectin levels were lower in Foxo1 +/− and Foxo1 +/− ; Notch1 +/− animals ( Supplementary  Table 1 ). Total body fat content was unchanged, but epididymal fat weight was greater in Foxo1 +/− and Foxo1 +/− ; Notch1 +/− animals.
Insulin sensitivity in clamped Foxo1 +/− ; Notch1 +/− mice We next performed hyperinsulinemic-euglycemic clamps. Foxo1 +/− ; Notch1 +/− mice required 1.6-and 4.5-fold greater glucose infusion rates than Foxo1 +/− and WT mice, respectively, to maintain euglycemia ( Fig. 2a) . Likewise, HGP was inhibited, and glucose disposal stimulated, to a greater extent in Foxo1 +/− ; Notch1 +/− mice than in Foxo1 +/− mice, although both groups were more insulin sensitive than WT littermates ( Fig. 2b) . Muscle 2-deoxyglucose uptake was greater in Foxo1 +/− ; Notch1 +/− mice ( Fig. 2c) , as was glycogen synthesis ( Supplementary Table 2 ), resulting in hepatic glycogen levels twofold higher than in WT or Foxo1 +/− mice ( Fig. 2d) .
Unlike with HFD-fed mice, there was no detectable difference between chow-fed Foxo1 +/− and Foxo1 +/− ; Notch1 +/− mice, probably because of the sensitivity of the clamp technique, as demonstrated by negative HGP in clamped conditions ( Supplementary Table 3 ).
To identify mechanisms of reduced HGP in Foxo1 +/− ; Notch1 +/− mice, we analyzed G6pc and Pck1 expression. In fasted chow-fed ( Fig. 2e ) and HFD-fed cohorts ( Fig. 2f) , G6pc levels were lower in Foxo1 +/− ; Notch1 +/− than Foxo1 +/− and WT mice, with correspondingly lower protein levels (data not shown). Pck1 expression was unaffected.
Liver-specific Rbp-Jk knockout partially prevents insulin resistance
To test the hypothesis that hepatic Notch signaling affects insulin sensitivity, we generated mice lacking the Notch effector Rbp-Jκ or FoxO1 in liver, using Albumin-cre transgenic mice to delete Rbpj (L-Rbpj) or Foxo1 (L-Foxo1) 'floxed' alleles, (Supplementary Fig. 3a-c) 17 . L-Rbpj mice showed no abnormalities in development, liver function tests or histological analysis compared to controls ( Supplementary Fig. 3d,e ). With HFD, L-Rbpj mice showed normal weight gain and body composition ( Fig. 3a,b ), but lower insulin levels than controls in the presence of similar serum glucose levels ( Fig. 3c,d) , and greater glucose tolerance than controls ( Fig. 3e) . Insulin tolerance test results were unaltered in L-Rbpj animals (data not shown). L-Rbpj livers showed greater Akt1 phosphorylation and lower fasted G6pc protein levels, indicative of increased hepatic insulin sensitivity (Fig. 3f) . These data indicate that ablation of hepatic Notch signaling protects from dietinduced insulin resistance.
Notch1 induces G6pc expression in a FoxO1-dependent manner
We transduced primary mouse hepatocytes with adenoviruses expressing N1-IC (constitutively active Notch1 mutant) 18 , FoxO1-ADA (constitutively active FoxO1 mutant) 19 or GFP and analyzed gluconeogenic gene expression. Consistent with previous studies, transduction with FoxO1-ADA increased G6pc expression 19 , whereas transduction with N1-IC did not (Fig. 4a) . The combination of N1-IC and FoxO1-ADA synergistically induced greater G6pc expression than FoxO1-ADA alone ( Fig. 4a ) and increased glucose release into culture medium (Supplementary Fig. 4a ). We also saw synergistic induction of canonical Notch targets, but not traditional FoxO1 targets such as Pck1 or Igfbp1 ( Fig.4a and Supplementary Fig. 4b) , a finding recapitulated in luciferase assays using promoters containing either Rbp-Jκ ( Supplementary Fig. 4c ) or FoxO1 binding sites ( Supplementary  Fig. 4d ). When cotransduced with a mutant FoxO1 that was deficient in DNA binding and constitutively nuclear (FoxO1-ADA-DBD) 16 , N1-IC did not induce G6pc (data not shown), indicating that Notch1 requires FoxO1 DNA binding to regulate G6pc.
To delineate the requirement for FoxO1 in Notch1-induced expression of G6pc, we performed luciferase assays using G6pc-promoter reporter constructs. The G6pc promoter contains a conserved Rbp-Jκ binding element 1.1 kilobases (kb) upstream of the transcriptional start site. N1-IC induced luciferase activity only when we used constructs containing both Rbp-Jκ as well as functional FoxO1 binding sites (Fig. 4b) .
We saw similar results using recombinant Delta-like ligand-4 (rDLL4), which activates endogenous Notch signaling ( Fig. 4c) .
Rbp-Jk binds to the G6pc promoter during fasting
On the basis of our luciferase data, we hypothesized that Rbp-Jκ directly binds to the G6pc promoter. Chromatin immunoprecipitation (ChIP) experiments showed a fourfold enrichment of Rbp-Jκ binding to a G6pc promoter sequence containing the putative Rbp-Jκ element in control and L-Foxo1, but not L-Rbpj mice (Fig. 4d) . No binding was seen in other regions of the G6pc promoter (data not shown). Consistent with increased hepatic Notch1 activation in the fasted state ( Fig. 1a) , this binding occurred only during fasting ( Fig. 4e) .
Gain of hepatic Notch1 function leads to insulin resistance
As adenovirus-mediated gene delivery leads to hepatocyte-predominant expression, we used this technique to determine the effects of N1-IC in liver 20 . Modest hepatic overexpression of Notch1 protein (Supplementary Fig. 4e ) increased fasted and refed glucose and insulin levels ( Fig. 4f,g) , suggesting insulin resistance. We noted increased expression of G6pc in livers of mice transduced with N1-IC, as well as some (Igfbp1) but not all FoxO1 targets (Fig. 4h) , providing further evidence that Notch1 regulates hepatic gluconeogenesis by inducing G6pc.
If the N1-IC adenovirus acted in an Rbp-Jκ-dependent manner to promote HGP, one would predict that it would be unable to do so in L-Rbpj mice. Indeed, hepatic N1-IC transduction in L-Rbpj mice did not increase plasma insulin (Fig. 4i) or expression of Notch targets and gluconeogenic genes (Fig. 4j) .
g-secretase inhibitors reduce HGP and raise glucose tolerance
After ligand binding, Notch receptor heterodimers dissociate and undergo sequential cleavage by membrane-bound ADAM (also known as TACE) and γ-secretase complex 9 . Notch receptor dimerization is calcium-dependent, and chelation with EDTA causes ligand-independent Notch activation 21 . We activated endogenous Notch1 by treating pri-mary hepatocytes with EDTA to generate NICD; this was prevented when we cotreated them with Compound E, a cell-permeable γsecretase inhibitor (GSI; Fig. 5a ) 22 . EDTA treatment increased Notch target and G6pc expression in a GSI-inhibitable manner (Fig. 5b) .
In the absence of EDTA, with only physiologic Notch1 activation in serum-free conditions, GSI treatment inhibited Notch target and G6pc expression, decreased glucose production and altered the dose-response curve of insulin to suppress glucose release ( Fig. 5c-e ). GSI lowered glucose output from hepatocytes derived from control and L-Foxo1 mice, but not L-Rbpj mice, as well as from hepatocytes expressing FoxO1 shRNA, indicating that the GSI's effects are Notchdependent, but FoxO1-independent ( Fig. 5f,g) . We next evaluated the in vivo effects of dibenzazepine (DBZ), a well-characterized and bioavailable GSI 23 . After a single dose of DBZ, WT mice had lower fasting and refed plasma glucose levels; a 5-d course of DBZ yielded similar reductions in fasting glucose, without altered insulin levels or body weight (Supplementary Fig. 5a-c) . Consistent with decreased HGP, DBZ-treated animals showed markedly greater glucose tolerance ( Fig. 6a and Supplementary Fig. 5d) , accompanied by marked reduction in expression of G6pc, Pck1 and other Notch-and FoxO1-specific targets (Fig. 6b) . DBZ treatment resulted in transient hepatic glycogen accumulation (probably a consequence of reduced glycogenolysis) as well as mild intestinal metaplasia ( Supplementary Fig. 5e,f) 24 . To test whether GSIs would be able to reverse the effects of chronic insulin resistance, we treated diet-induced obese (DIO) and leptin-deficient ob/ob mice with DBZ. Both cohorts showed markedly lower glucose levels (Fig. 6c) ; ob/ob mice additionally had lower insulin levels (Fig. 6d) . And both groups showed greater glucose tolerance with GSI ( Fig. 6e,f) , suggestive of increased insulin sensitivity. Chronic, intermittent treatment with DBZ did not alter food intake, body weight or body composition (Supplementary Fig. 6a-c) but was similarly effective in raising glucose tolerance (Fig. 6g, Supplementary Fig. 6d ), suggesting that GSI effects do not wane over time. Glucose and insulin measurements in the ad libitum fed state showed that the hypoglycemic effect of GSI lasts ~24 h and is associated with lower insulin levels ( Fig. 6g-i) . Hepatic phosphorylation of Akt1 and IRS1 were increased, suggesting greater hepatic insulin sensitivity with GSI treatment (Fig. 6j) .
DISCUSSION
Although the beneficial effect of FoxO1 inhibition on glucose homeostasis is recognized 7, 25 , the role of Notch signaling in this process, and the regulation of the hepatic Notch pathway by nutritional status, are novel findings of this work. Combined activation of Notch1 and FoxO1 signaling with fasting and in insulin resistance is consistent with the hypothesis that they coregulate key metabolic pathways. Additionally, clamp studies point to stepwise effects from WT to Foxo1 +/− to Foxo1 +/− ; Notch1 +/− mice in suppressing HGP and promoting muscle glucose disposal. The contribution of extrahepatic and cell-nonautonomous mechanisms to this complex phenotype remains to be determined, but the present data provide a strong mechanistic foundation to explore the therapeutic potential of targeting the Notch pathway in diabetes.
Multiple target genes probably account for the improved hepatic insulin sensitivity of Foxo1 +/− ; Notch1 +/− mice, owing to the pleiotropic functions of the insulin-FoxO1 and Notch1-Rbp-Jκ pathways 9, 26 .
A key finding of the present work is the repression of G6pc, a known transcriptional target of FoxO1 (ref. 20) whose expression under both basal and hormone-stimulated conditions is reduced by >90% in hepatocytes from L-Foxo1 mice (U.B.P. and D.A., unpublished data) or after acute FoxO1 inhibition through shRNA 8 . Mechanistically, the most parsimonious explanation is that inhibition of G6pc in Foxo1 +/− ; Notch1 +/− mice is secondary to reduced FoxO1 function. However, we show that G6pc is a direct Notch target and that Rbp-Jκ binds to the G6pc promoter in a FoxO1-independent manner in the fasted state, consistent with a physiologic role of hepatic Notch in the regulation of HGP. Additional lines of evidence strengthen this conclusion: first, combined Notch1 and FoxO1 gain of function synergistically induced G6pc, without affecting other FoxO1 targets (Pck1 and Igfbp1) or An unsettled question is whether FoxO1 requires Rbp-Jκ for maximal stimulation of G6pc transcription. GSI treatment of FoxO1deficient primary hepatocytes curtailed G6pc expression and glucose production, indicating that the effects of this inhibitor are independent of FoxO1. Additionally, Rbp-Jκ ablation improved glucose tolerance in vivo and reduced G6pc expression in hepatocytes (data not shown), suggesting that inhibition of hepatic Notch signaling can affect insulin sensitivity independently of FoxO1 levels. Nevertheless, our data in hepatocytes demonstrate the requirement for FoxO1 in G6pc induction with both ligand-dependent (recombinant DLL4) and ligand-independent (N1-IC) activation of Notch, suggesting that both transcription factors are necessary for the full phenotype of dietinduced hepatic insulin resistance. Foxo1 +/− ; Notch1 +/− mice show a ~35% decrease in fasting G6pc expression, associated with ~20% decrease of glucose levels, twofold increase of hepatic glycogen, and reduced pyruvate-to-glucose conversion in vivo and in primary hepatocytes, suggestive of reduced gluconeogenesis and glycogenolysis. These findings are consistent with knockdown studies in which a similar decrease in G6pc levels and enzymatic activity led to a 15% reduction of glycemia and a 50% increase of liver glycogen 27 . Foxo1 +/− ; Notch1 +/− mice also phenocopy the decrease in G6pc expression, but not the hepatosteatosis and dyslipidemia observed in mice lacking hepatic steroid receptor coactivator-2 (ref. 28) .
Decreased HGP in Foxo1 +/− ; Notch1 +/− mice is also attributable to mechanisms independent of gluconeogenesis, such as decreased expression of sterol regulatory element binding transcription factor 1 (Srebf1) and its transcriptional targets 29, 30 (U.B.P. and D.A., unpublished data). In addition, HFD-fed FoxO1 +/− and Foxo1 +/− ; Notch1 +/− mice showed increased glycolysis in clamp studies. These pathways probably contribute to the overall phenotype of Foxo1 +/− ; Notch1 +/− and L-Rbpj mice.
Clamp experiments also show that combined FoxO1 and Notch1 haploinsufficiency coordinately increases muscle glucose disposal, indicating that the improved insulin sensitivity in these animals is not unique to the liver. Ablation of muscle FoxO1 promotes formation of fast-twitch fibers 16 . Should similar changes occur in FoxO1 +/− and Foxo1 +/− ; Notch1 +/− animals, they would contribute to raising glucose utilization. Foxo1 +/− mice also show low adiponectin, resulting either from direct FoxO1 transcriptional effects or from changes in visceral adiposity 31, 32 . Given the insulin-like effects of adiponectin on HGP 33, 34 , this decrease may partly mask the full extent of changes in HGP seen in FoxO1 +/− and Foxo1 +/− ; Notch1 +/− mice.
FoxO1 remains an elusive drug target owing to its lack of ligand-binding domain, complex regulation and broad transcriptional signature. Inhibition of Notch thus provides an alternative path to modulate FoxO1-dependent gluconeogenesis, as demonstrated by improved glucose tolerance in L-Rbpj mice. Unlike FoxOs, components of the Notch pathway have been validated as drug targets, and GSIs continue to elicit interest for the treatment of Alzheimer's disease 35 and T cell acute lymphoblastic leukemia 22, 36 . Although there currently are significant limitations for the use of these compounds, the improvement in liver glucose metabolism provides impetus to identify compounds with preferential hepatic effects, resulting from either distribution properties or preference for liverenriched Notch receptors. We envision that the availability of new Notch therapeutic agents 36, 37 will increase specificity and limit toxicity in targeting this pathway, thus paving the way for their use as insulin sensitizers.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
